EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms

Tanvi Brar, Charles Olowookere, Dat Le, Menglin Xu, Bhavana Konda iD, Vineeth Sukrithan iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Tanvi Brar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Immune Checkpoint Inhibitors, Genomics, Biomarkers, Tumor. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs), but predictive biomarkers of long-term overall survival (OS) are currently lacking.

Methods

We derived a genomic scoring system using a retrospective cohort of 54 NEN patients treated with nivolumab and/or ipilimumab, alongside a chemotherapy-only control (n = 15) and pan-cancer validation cohort (n = 1661). An overall genomic score (GS-O) combining positive (GS-P) and negative response genes (GS-N) was calculated.

Results

In the ICI cohort, patients with GS-O ≥ 2 had significantly better outcomes: median OS was not reached, compared to 3.9 months for low scores (HR = 0.007, P < .001). After multivariate adjustment, GS-P was independently associated with improved OS while GS-N showed a trend towards worsened OS. Importantly, GS-O ≥ 2 did not predict survival in the chemotherapy-alone cohort but was validated as independently predictive in the pan-cancer validation dataset (HR = 0.92, P < .001).

Conclusion

This study establishes a novel genomic score to predict OS in NENs treated with ICI with important pan-cancer implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsImmune Checkpoint InhibitorsGenomicsBiomarkers, TumorHumansFemaleMaleRetrospective StudiesMiddle AgedPrognosisAgedNivolumab

Stichwörter der Autor:innen

biomarkergenomic scoreimmune checkpoint inhibitorimmunotherapyipilimumabneuroendocrine neoplasmsnivolumab

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorNivolumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
  • Post Baccalaureate Program, Ohio State University, Columbus, OH 43210, United States.
  • Department of Pharmacy, Robert H. Lurie Comprehensive Cancer Center of Northwestern, Chicago, IL 60611, United States.
  • Boston Medical Center, Boston, MA 02118, United States.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and Arthur G. James Cancer Center, Columbus, OH 43210, United States.

ORCID-Profile: Bhavana Konda, Vineeth Sukrithan

Zitieren

APA

Brar, T., Olowookere, C., Le, D., Xu, M., Konda, B., & Sukrithan, V. (2026). Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms. The Oncologist. https://doi.org/10.1093/oncolo/oyag324

Vancouver

Brar T, Olowookere C, Le D, Xu M, Konda B, Sukrithan V. Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms. The Oncologist. 2026. doi:10.1093/oncolo/oyag324

BibTeX
@article{Brar2026,
  author = {Brar, Tanvi and Olowookere, Charles and Le, Dat and Xu, Menglin and Konda, Bhavana and Sukrithan, Vineeth},
  title = {Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag324}
}
Kostenlos starten →